Interventional Radiology Imaging

What Is the Best Intervention for Acute Iliofemoral DVT with May-Thurner Syndrome?

·
What Is the Best Intervention for Acute Iliofemoral DVT with May-Thurner Syndrome?

A 48-year-old woman presents to the emergency department with five days of progressive, painful swelling in her left leg. The leg is tense and discolored. A CT venogram confirms an extensive deep vein thrombosis (DVT) extending from the common femoral vein into the common iliac vein. Crucially, the images also demonstrate significant compression of the left common iliac vein by the overlying right common iliac artery. You’ve confirmed the diagnosis: acute iliofemoral DVT in the setting of May-Thurner syndrome. The critical decision now is not just whether to treat, but how to intervene to achieve the best long-term outcome. This article details the clinical workflow for this specific scenario, where the American College of Radiology (ACR) rates Catheter-Directed Thrombolysis (CDT) or Pharmacomechanical Thrombectomy (PMT) as Usually Appropriate.

Who Fits This Clinical Scenario?

This guidance applies specifically to patients meeting a precise set of criteria: acute symptoms of deep vein thrombosis (less than 14 days in duration), thrombus located in the iliofemoral venous segment, and cross-sectional imaging (like CT or MR venography) that confirms an underlying anatomic variant consistent with May-Thurner syndrome (also known as iliac vein compression syndrome).

This workflow is distinct from other DVT presentations. This article does not apply if:

  • The patient has limb-threatening ischemia (phlegmasia cerulea dolens). This is a vascular emergency that may require more aggressive or surgical intervention and follows a different ACR pathway.
  • Symptoms are chronic. If the patient has had persistent symptoms for months after initial anticoagulation, they fit the scenario for chronic iliofemoral DVT, which involves different treatment considerations.
  • The DVT is isolated to the femoropopliteal segment. Thrombosis below the inguinal ligament without iliac involvement often has a different risk profile and management strategy.
  • There is no evidence of iliac vein compression. An unprovoked iliofemoral DVT without an underlying anatomic cause may be managed differently, often starting with anticoagulation alone.

Correctly identifying the patient’s presentation as acute, iliofemoral, and secondary to a clear anatomic driver is key to applying this specific management pathway.

What Diagnoses Are You Working Up in This Scenario?

At this stage, the primary diagnosis of acute iliofemoral DVT is confirmed. The clinical workup is focused on understanding the underlying cause and preventing long-term complications. The differential considerations are less about what the condition is and more about why it occurred and what it portends.

Iliofemoral DVT Secondary to May-Thurner Syndrome: This is the principal diagnosis. The compression of the left common iliac vein by the right common iliac artery creates a zone of turbulent flow and venous stasis, predisposing the patient to thrombosis. This mechanical obstruction is the primary treatment target, as simply dissolving the clot without addressing the compression leads to a high likelihood of recurrence.

Underlying Hypercoagulable State: While May-Thurner syndrome provides the anatomic trigger, it is essential to consider if a systemic prothrombotic condition is also present. This is particularly true in patients without other DVT risk factors (like recent surgery, trauma, or immobility). A workup for inherited or acquired thrombophilias may be warranted, as it can influence the duration and intensity of post-procedural anticoagulation.

Post-Thrombotic Syndrome (PTS): This is not a differential diagnosis but rather the primary long-term complication the intervention aims to prevent. PTS is a chronic condition of limb pain, swelling, skin changes, and venous ulcers caused by venous hypertension from damaged valves and persistent obstruction. Aggressive, early clot removal in extensive iliofemoral DVT is performed with the goal of preserving valvular function and preventing the debilitating sequelae of PTS.

Why Is CDT/PMT with Stenting the Recommended Intervention for This Presentation?

For a patient with acute iliofemoral DVT driven by May-Thurner anatomy, the ACR designates Catheter-Directed Thrombolysis (CDT) or Pharmacomechanical Thrombectomy (PMT), with or without stent placement, as Usually Appropriate. This recommendation is based on the need to address both the thrombus burden and the underlying mechanical obstruction.

CDT involves infusing a thrombolytic agent directly into the clot via a catheter, while PMT uses a device to mechanically break up and aspirate the clot, often with simultaneous lytic infusion. These endovascular techniques are highly effective at rapidly debulking large-volume thrombus, which restores venous flow and can alleviate acute symptoms quickly. More importantly, removing the clot unmasks the underlying compression, which can then be treated definitively with venous stent placement. This combined approach directly targets the root cause of the DVT.

In contrast, two other options are rated lower for this specific scenario:

  • Anticoagulation alone is rated May be appropriate. While anticoagulation prevents clot propagation and reduces the risk of pulmonary embolism, it does not actively remove the existing thrombus or relieve the mechanical compression. In the setting of May-Thurner syndrome, this leaves the patient with a high risk of re-thrombosis and the development of severe post-thrombotic syndrome.
  • Hybrid surgical thrombectomy with stenting is also rated May be appropriate. This more invasive approach may be considered in select cases but is generally reserved for situations where endovascular techniques are not feasible or have failed.

These interventional procedures involve fluoroscopy, which uses ionizing radiation. However, the benefits of preventing a lifelong, debilitating condition like severe PTS are generally considered to far outweigh the procedural radiation risks. The procedures are performed by an interventional radiologist who can provide a comprehensive treatment plan, from thrombus removal to stent placement and follow-up.

What’s Next After CDT/PMT with Stenting? Downstream Workflow

The management of the patient does not end after the procedure. The post-intervention workflow is critical for ensuring long-term success and patency of the treated vein.

If the procedure is technically successful (thrombus removed, stent placed, flow restored): The patient will be started on a therapeutic anticoagulation regimen. The specific agent and duration will depend on institutional protocols and whether an underlying hypercoagulable state was identified. Close follow-up with venous duplex ultrasound is essential to monitor stent patency, typically at one, three, six, and twelve months post-procedure, and then annually. The patient should also be educated on the importance of compliance with anticoagulation and the use of compression stockings.

If the procedure is unsuccessful or only partially successful: If significant residual thrombus or obstruction remains, further intervention may be required. This could involve another session of thrombolysis or consideration of alternative strategies. The key is to not abandon the goal of restoring unobstructed inline flow to the inferior vena cava.

If the patient develops recurrent symptoms after a successful procedure: This should trigger an urgent evaluation with duplex ultrasound or CT/MR venography to assess for in-stent restenosis or recurrent thrombosis. Early detection is key, as these issues can often be managed with repeat endovascular intervention.

Pitfalls to Avoid (and When to Get Help)

Navigating this clinical scenario requires avoiding several common pitfalls to ensure optimal patient outcomes.

  1. Delaying Intervention: The efficacy of thrombolysis and thrombectomy decreases significantly as the clot organizes. For this reason, the ACR criteria specify “symptoms less than 14 days.” Delaying the decision to intervene can lead to a less effective procedure and a higher risk of post-thrombotic syndrome.
  2. Under-treating the Lesion: Simply performing thrombolysis without stenting the underlying iliac vein compression is a frequent cause of treatment failure. The May-Thurner anatomy is the fundamental problem; failing to address it with a stent almost guarantees re-thrombosis.
  3. Inadequate Anticoagulation Post-Procedure: Prematurely stopping anticoagulation is a major risk factor for stent thrombosis. A clear, long-term anticoagulation plan must be established and communicated to the patient and their primary care physician.

If a patient presents with a massively swollen, cyanotic leg (phlegmasia cerulea dolens) or signs of compromised arterial inflow, this represents a true vascular emergency. Escalate immediately to an interventional radiologist and vascular surgeon for emergent intervention, as limb loss is a significant risk.

Related ACR Topics and Tools

This article covers one specific variant within a broader topic. For a comprehensive overview and to compare this scenario with others, please consult the resources below. The ACR provides detailed guidance that can help you select the right study for your patient’s unique presentation.

Frequently Asked Questions

Why is the 14-day symptom window so important for this intervention?

The 14-day window defines the ‘acute’ phase of a deep vein thrombosis. Within this period, the thrombus is relatively fresh and unorganized, making it much more susceptible to dissolution by thrombolytic drugs (CDT) or removal by mechanical devices (PMT). After 2-4 weeks, the clot begins to organize and adhere to the vein wall, making it significantly more difficult and less effective to remove, increasing the risk of permanent vein damage.

Is stenting always necessary if May-Thurner syndrome is found?

Yes, in the context of treating an acute DVT caused by May-Thurner anatomy, stenting is considered essential. The mechanical compression is the underlying cause of the thrombosis. Simply removing the clot with CDT or PMT without addressing the compression point leaves the patient at an extremely high risk for re-thrombosis. The stent acts as a scaffold to hold the vein open and correct the anatomic problem.

What are the main risks of CDT/PMT with stenting?

The primary risks include bleeding, which can occur at the access site or systemically (including intracranial hemorrhage), though the risk is lower with catheter-directed techniques than systemic thrombolysis. Other risks include contrast-induced nephropathy, access site complications like pseudoaneurysm or hematoma, and pulmonary embolism during the procedure if a piece of clot breaks free. Long-term risks include in-stent restenosis or thrombosis.

Can this procedure be performed on an outpatient basis?

Typically, no. Catheter-directed thrombolysis often requires a continuous infusion of a lytic agent over 24-48 hours, necessitating admission to a monitored setting like an ICU or step-down unit. Single-session pharmacomechanical thrombectomy may sometimes allow for a shorter hospital stay, but patients still require close observation post-procedure for bleeding and other complications.

Does every patient with left iliac vein compression on a CT scan have May-Thurner syndrome?

Not necessarily. A mild degree of left common iliac vein compression is a common anatomic finding in many asymptomatic individuals. The term ‘May-Thurner syndrome’ is typically reserved for patients who have this anatomy and develop clinical sequelae, such as DVT or chronic venous insufficiency. The presence of significant thrombus in this location is what makes the anatomic finding clinically actionable.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 26, 2026